An Attempt to Stretch the Benefit: Rechallenge with PARP Inhibitors in Ovarian Cancer

Clin Cancer Res. 2023 Jul 14;29(14):2563-2566. doi: 10.1158/1078-0432.CCR-23-0652.

Abstract

PARP inhibitors exploit synthetic lethality in homologous recombination-deficient (HDR) cells and are standard-of-care treatment in newly diagnosed and relapsed epithelial ovarian cancer (EOC). A recent article demonstrated that a second course of olaparib can be safely administered to women with BRCA-mutated EOC. See related article by Morgan et al., p. 2602.

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • BRCA1 Protein / genetics
  • BRCA2 Protein / genetics
  • Carcinoma, Ovarian Epithelial / drug therapy
  • Female
  • Germ Cells
  • Humans
  • Neoplasm Recurrence, Local
  • Ovarian Neoplasms* / drug therapy
  • Ovarian Neoplasms* / genetics
  • Phthalazines / adverse effects
  • Poly(ADP-ribose) Polymerase Inhibitors* / adverse effects

Substances

  • Poly(ADP-ribose) Polymerase Inhibitors
  • olaparib
  • BRCA1 protein, human
  • BRCA1 Protein
  • BRCA2 protein, human
  • BRCA2 Protein
  • Phthalazines